IFNA1 and systemic lupus erythematosus: Among SLE patients of non‐European ancestry, we identified a small but very distinctive cluster, NEA‐1 (low IFN, high neutrophil/myeloid lineage/inflammation scores), which demonstrated the poorest response to rituximab.